(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of -3.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Tango Therapeutics's revenue in 2025 is $40,991,000.On average, 4 Wall Street analysts forecast TNGX's revenue for 2025 to be $2,603,303,261, with the lowest TNGX revenue forecast at $2,338,062,678, and the highest TNGX revenue forecast at $2,764,051,845. On average, 4 Wall Street analysts forecast TNGX's revenue for 2026 to be $3,065,929,664, with the lowest TNGX revenue forecast at $2,338,062,678, and the highest TNGX revenue forecast at $4,560,143,573.
In 2027, TNGX is forecast to generate $4,156,917,187 in revenue, with the lowest revenue forecast at $3,404,661,508 and the highest revenue forecast at $4,909,172,865.